Loading company
Just reported
Q4 FY2026 results
From Becton, Dickinson's results release of November 5, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
$5.27B
-36% y/y
+5.8% q/qGuided
—
No guide given
EPS, GAAP
Actual
$2.54
+48% y/y
+85% q/qGuided
—
No guide given
EPS, adjusted: $2.52
Operating income, GAAP
Actual
$1.03B
-12% y/y
+56% q/qGuided
—
No guide given
Company outlook
Full year 2027
- EPS, adjusted$13.10 – $13.30First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Becton, Dickinson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.$152.5BA+
MDLNMedline Inc.$52.6BA
ALCAlcon Inc.$35BA
BLCOBausch & Lomb Corp$7.6BA-
ATRCAtriCure, Inc.$2.9BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
Built from Becton, Dickinson And Company’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
